48.88 USD
-0.45 (-0.91%)
48.88 USD
0 (0%)
COLL gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. While COLL has a great profitability rating, there are some minor concerns on its financial health. COLL scores decently on growth, while it is valued quite cheap. This could make an interesting combination. With these ratings, COLL could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
In the past year COLL was profitable.
In the past year COLL had a positive cash flow from operations.
COLL had positive earnings in 4 of the past 5 years.
COLL had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
COLL has a Return On Assets of 3.64%. This is amongst the best in the industry. COLL outperforms 83.85% of its industry peers.
Looking at the Return On Equity, with a value of 21.27%, COLL belongs to the top of the industry, outperforming 91.15% of the companies in the same industry.
With an excellent Return On Invested Capital value of 9.10%, COLL belongs to the best of the industry, outperforming 88.02% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for COLL is in line with the industry average of 12.85%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.64% | ||
| ROE | 21.27% | ||
| ROIC | 9.1% |
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
1.3 Margins
Looking at the Profit Margin, with a value of 7.72%, COLL belongs to the top of the industry, outperforming 82.81% of the companies in the same industry.
In the last couple of years the Profit Margin of COLL has declined.
COLL has a Operating Margin of 20.74%. This is amongst the best in the industry. COLL outperforms 88.54% of its industry peers.
COLL's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 57.22%, COLL is in the better half of the industry, outperforming 67.71% of the companies in the same industry.
COLL's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.74% | ||
| PM (TTM) | 7.72% | ||
| GM | 57.22% |
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
2. Health
2.1 Basic Checks
COLL has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
COLL has less shares outstanding than it did 1 year ago.
The number of shares outstanding for COLL has been reduced compared to 5 years ago.
Compared to 1 year ago, COLL has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.51, we must say that COLL is in the distress zone and has some risk of bankruptcy.
COLL has a Altman-Z score of 1.51. This is comparable to the rest of the industry: COLL outperforms 54.69% of its industry peers.
The Debt to FCF ratio of COLL is 2.79, which is a good value as it means it would take COLL, 2.79 years of fcf income to pay off all of its debts.
COLL has a better Debt to FCF ratio (2.79) than 90.63% of its industry peers.
A Debt/Equity ratio of 2.71 is on the high side and indicates that COLL has dependencies on debt financing.
COLL has a Debt to Equity ratio of 2.71. This is amonst the worse of the industry: COLL underperforms 81.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.71 | ||
| Debt/FCF | 2.79 | ||
| Altman-Z | 1.51 |
ROIC/WACC0.98
WACC9.25%
2.3 Liquidity
A Current Ratio of 1.36 indicates that COLL should not have too much problems paying its short term obligations.
COLL has a Current ratio of 1.36. This is in the lower half of the industry: COLL underperforms 73.96% of its industry peers.
A Quick Ratio of 1.27 indicates that COLL should not have too much problems paying its short term obligations.
The Quick ratio of COLL (1.27) is worse than 70.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.27 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 30.73% over the past year.
The Earnings Per Share has been growing by 154.78% on average over the past years. This is a very strong growth
COLL shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.34%.
The Revenue has been growing by 16.31% on average over the past years. This is quite good.
EPS 1Y (TTM)30.73%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%39.75%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%31.42%
3.2 Future
The Earnings Per Share is expected to decrease by -1.58% on average over the next years.
The Revenue is expected to grow by 3.62% on average over the next years.
EPS Next Y19.18%
EPS Next 2Y12.57%
EPS Next 3Y-4.69%
EPS Next 5Y-1.58%
Revenue Next Year24.31%
Revenue Next 2Y13.52%
Revenue Next 3Y2.59%
Revenue Next 5Y3.62%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 6.80, the valuation of COLL can be described as very cheap.
94.79% of the companies in the same industry are more expensive than COLL, based on the Price/Earnings ratio.
COLL is valuated cheaply when we compare the Price/Earnings ratio to 26.39, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 5.98, the valuation of COLL can be described as very cheap.
Based on the Price/Forward Earnings ratio, COLL is valued cheaply inside the industry as 95.31% of the companies are valued more expensively.
COLL's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.84.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.8 | ||
| Fwd PE | 5.98 |
4.2 Price Multiples
COLL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. COLL is cheaper than 97.92% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, COLL is valued cheaper than 96.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.34 | ||
| EV/EBITDA | 5.04 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
COLL has an outstanding profitability rating, which may justify a higher PE ratio.
COLL's earnings are expected to decrease with -4.69% in the coming years. This may justify a cheaper valuation.
PEG (NY)0.35
PEG (5Y)N/A
EPS Next 2Y12.57%
EPS Next 3Y-4.69%
5. Dividend
5.1 Amount
COLL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
48.88
-0.45 (-0.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners120.37%
Inst Owner Change0.64%
Ins Owners1.43%
Ins Owner Change-0.82%
Market Cap1.55B
Revenue(TTM)757.07M
Net Income(TTM)58.44M
Analysts81.82
Price Target49.64 (1.55%)
Short Float %18.91%
Short Ratio11.95
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.9%
Min EPS beat(2)1.88%
Max EPS beat(2)7.92%
EPS beat(4)4
Avg EPS beat(4)6.15%
Min EPS beat(4)1.88%
Max EPS beat(4)12.85%
EPS beat(8)7
Avg EPS beat(8)12.99%
EPS beat(12)9
Avg EPS beat(12)-15.06%
EPS beat(16)10
Avg EPS beat(16)-21.97%
Revenue beat(2)2
Avg Revenue beat(2)5.22%
Min Revenue beat(2)1.9%
Max Revenue beat(2)8.53%
Revenue beat(4)3
Avg Revenue beat(4)2.75%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)8.53%
Revenue beat(8)4
Avg Revenue beat(8)0.8%
Revenue beat(12)6
Avg Revenue beat(12)0.28%
Revenue beat(16)8
Avg Revenue beat(16)-3.75%
PT rev (1m)9.12%
PT rev (3m)9.12%
EPS NQ rev (1m)-0.33%
EPS NQ rev (3m)7.88%
EPS NY rev (1m)-15.27%
EPS NY rev (3m)-8.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.69%
Revenue NY rev (1m)4.07%
Revenue NY rev (3m)3.37%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.8 | ||
| Fwd PE | 5.98 | ||
| P/S | 2.04 | ||
| P/FCF | 5.34 | ||
| P/OCF | 5.31 | ||
| P/B | 5.62 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.04 |
EPS(TTM)7.19
EY14.71%
EPS(NY)8.17
Fwd EY16.72%
FCF(TTM)9.15
FCFY18.72%
OCF(TTM)9.2
OCFY18.83%
SpS23.95
BVpS8.69
TBVpS-18.86
PEG (NY)0.35
PEG (5Y)N/A
Graham Number37.5
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.64% | ||
| ROE | 21.27% | ||
| ROCE | 13.6% | ||
| ROIC | 9.1% | ||
| ROICexc | 12.09% | ||
| ROICexgc | N/A | ||
| OM | 20.74% | ||
| PM (TTM) | 7.72% | ||
| GM | 57.22% | ||
| FCFM | 38.21% |
ROA(3y)2.08%
ROA(5y)4.15%
ROE(3y)14.01%
ROE(5y)18.34%
ROIC(3y)11.08%
ROIC(5y)9.32%
ROICexc(3y)16.99%
ROICexc(5y)14.94%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)16.56%
ROCE(5y)13.94%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y15.58%
ROICexc growth 5YN/A
OM growth 3Y43.71%
OM growth 5YN/A
PM growth 3Y-24.85%
PM growth 5YN/A
GM growth 3Y3.19%
GM growth 5Y11.47%
F-Score7
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.71 | ||
| Debt/FCF | 2.79 | ||
| Debt/EBITDA | 1.94 | ||
| Cap/Depr | 0.72% | ||
| Cap/Sales | 0.21% | ||
| Interest Coverage | 2.17 | ||
| Cash Conversion | 75.92% | ||
| Profit Quality | 495.01% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.27 | ||
| Altman-Z | 1.51 |
F-Score7
WACC9.25%
ROIC/WACC0.98
Cap/Depr(3y)142.93%
Cap/Depr(5y)207.67%
Cap/Sales(3y)41.34%
Cap/Sales(5y)49.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.73%
EPS 3Y154.78%
EPS 5YN/A
EPS Q2Q%39.75%
EPS Next Y19.18%
EPS Next 2Y12.57%
EPS Next 3Y-4.69%
EPS Next 5Y-1.58%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y31.63%
Revenue growth 5Y16.31%
Sales Q2Q%31.42%
Revenue Next Year24.31%
Revenue Next 2Y13.52%
Revenue Next 3Y2.59%
Revenue Next 5Y3.62%
EBIT growth 1Y-18.86%
EBIT growth 3Y89.16%
EBIT growth 5YN/A
EBIT Next Year154.57%
EBIT Next 3Y23.61%
EBIT Next 5Y18.85%
FCF growth 1Y8.55%
FCF growth 3Y25.98%
FCF growth 5Y56.88%
OCF growth 1Y8.67%
OCF growth 3Y25.54%
OCF growth 5Y49.12%
COLLEGIUM PHARMACEUTICAL INC / COLL FAQ
What is the ChartMill fundamental rating of COLLEGIUM PHARMACEUTICAL INC (COLL) stock?
ChartMill assigns a fundamental rating of 6 / 10 to COLL.
Can you provide the valuation status for COLLEGIUM PHARMACEUTICAL INC?
ChartMill assigns a valuation rating of 9 / 10 to COLLEGIUM PHARMACEUTICAL INC (COLL). This can be considered as Undervalued.
What is the profitability of COLL stock?
COLLEGIUM PHARMACEUTICAL INC (COLL) has a profitability rating of 8 / 10.
Can you provide the financial health for COLL stock?
The financial health rating of COLLEGIUM PHARMACEUTICAL INC (COLL) is 5 / 10.